Atriclip

US-based medical device firm Atricure has secured US Food and Drug Administration (FDA) 510(k) clearance for the AtriClip PRO2 Left Atrial Appendage (LAA) Exclusion System.

LAA closure is a treatment given by doctors to patients afflicted with atrial fibrillation, where an uncontrolled electrical impulse for the heartbeat results in the collection of blood in the pouch-like LAA which subsequently clots and once pumped out of the heart can cause a stroke.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The new AtriClip PRO2 system is said to feature an enhanced functionality which can obstruct the LAA during minimally-invasive surgical (MIS) procedures.

The system consists of an ambidextrous locking and trigger-style clip closing mechanism, handle-based active articulation levers, and a hoopless end effector.

The ambidextrous locking and trigger-style clip closing mechanism enables the operator to focus on the LAA while maneuvering the device.

The handle-based active articulation levers allow the operator to steer the end effector without removing the device.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The hoopless end effector improves anatomical visualisation, and makes the removal of the applier after deployment of the clip, easier.

"The new deployment system facilitates less invasive treatment of the LAA, including right chest approaches in conjunction with valve replacement and cardiac ablation procedures."

TriHealth Heart Institute Thoracic Surgery and General Surgery speclalist Dr Michael Smith said: "The AtriClip PRO2 system provides easier placement of the proven AtriClip LAA occlusion technology.

"The new deployment system facilitates less invasive treatment of the LAA, including right chest approaches in conjunction with valve replacement and cardiac ablation procedures."

AtriCure is claimed to be the first company to secure FDA clearance for a device designed specifically for obstructing the LAA.

Last year saw a growth of 45% in the sales of AtriClip products on a global basis as compared to the prior period in 2014. To date, AtriClip products have been used to treat more than 70,000 patients across the world.

Image: An atriclip attached to the left atrial appendage. Photo: courtesy of Hellerhoff.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact